These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10834025)

  • 1. Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer.
    Jacobs A; Gold P; Weiden P; Aboulafia D; Rudolph R; Picozzi V; Thompson J
    Cancer Invest; 2000; 18(5):417-21. PubMed ID: 10834025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
    Motzer RJ; Schwartz L; Law TM; Murphy BA; Hoffman AD; Albino AP; Vlamis V; Nanus DM
    J Clin Oncol; 1995 Aug; 13(8):1950-7. PubMed ID: 7636535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
    Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
    J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
    Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
    Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
    Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
    J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
    Stadler WM; Kuzel T; Dumas M; Vogelzang NJ
    J Clin Oncol; 1998 May; 16(5):1820-5. PubMed ID: 9586896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine in the treatment of metastatic renal cell carcinoma.
    Oevermann K; Buer J; Hoffmann R; Franzke A; Schrader A; Patzelt T; Kirchner H; Atzpodien J
    Br J Cancer; 2000 Sep; 83(5):583-7. PubMed ID: 10944596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
    Vaishampayan U; Flaherty L; Du W; Hussain M
    Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha].
    Paredes Espinoza M; Lippman SM; Kavanagh JJ; Delgadillo Madrueño F; Paredes Casillas P; Bañuelos Acosta O; Alvarez Márquez V; Buenrostro Ahued MA; de Alba Ayala I; Arias Castro G
    Rev Invest Clin; 1994; 46(2):105-11. PubMed ID: 8052740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials.
    Bacoyiannis C; Dimopoulos MA; Kalofonos HP; Nicolaides C; Aravantinos G; Bafaloukos D; Samelis G; Onyenadum A; Kiamouris Ch; Skarlos D; Pavlidis N; Triantafillidis A; Kosmidis P;
    Oncology; 2002; 63(2):130-8. PubMed ID: 12239447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial.
    Weiss GR; Liu PY; Alberts DS; Peng YM; Fisher E; Xu MJ; Scudder SA; Baker LH; Moore DF; Lippman SM
    Gynecol Oncol; 1998 Dec; 71(3):386-90. PubMed ID: 9887236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
    J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma.
    Wong M; Goldstein D; Woo H; Testa G; Gurney H
    Intern Med J; 2002 Apr; 32(4):158-62. PubMed ID: 11951927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervix.
    Hallum AV; Alberts DS; Lippman SM; Inclan L; Shamdas GJ; Childers JM; Surwit EA; Modiano M; Hatch KD
    Gynecol Oncol; 1995 Mar; 56(3):382-6. PubMed ID: 7705672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysis.
    Roigas J; Deger S; Taymoorian K; Wille AH; Johannsen M; Türk I; Schnorr D; Loening SA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):157-63. PubMed ID: 12804041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
    Garcia JA; Mekhail T; Elson P; Wood L; Bukowski RM; Dreicer R; Rini BI
    BJU Int; 2012 Jan; 109(1):63-9. PubMed ID: 21244601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.